We love to keep you in the loop on what is going on Alzheimer’s disease research and our latest studies. Here are the latest e-newsletters that have been sent to our readers and patients. If you are interested in our newsletter, please fill out the form below to get them directly to your inbox.
Despite decades of study, the underlying cause of Alzheimer’s continues to evade scientists. Until recently, the only drugs available to patients targeted the symptoms of
The Memory Advocate Peers program supports couples newly diagnosed with dementia. What should you do when your loved one is newly diagnosed with Alzheimer’s? A
Alzheimer’s anti-amyloid drug Leqembi (generic name lecanemab) was granted accelerated FDA approval last month. But, trials are still ongoing to verify the drug’s benefits to
Amyloid plaques are a hallmark of Alzheimer’s disease. The interesting thing is, not everyone who develops these plaques gets Alzheimer’s. Answering this question could reveal
The brain’s power generators, mitochondria, could hold the key to Alzheimer’s disease. Understanding them better is also shedding light on the potential of diabetes drugs
K2 Medical Research is recruiting for a Phase 2 trial of Alector and Abbvie’s new experimental Alzheimer’s drug, AL002. K2 is screening possible trial participants
Long-term care homes are looking for new ways to improve the lives of their residents. Using dogs and dog robots, scientists have found an unlikely
By: Simon Spichak With all the seemingly contradictory headlines, it is hard to tell whether coffee is good or bad for you. This article explores
K2 Med is recruiting for a new Phase 3 trial for Eli Lilly’s new Alzheimer’s drug donanemab. By: Simon Spichak K2 is screening possible trial
When it comes to music and the brain, there is a very special link. By: Simon Spichak When Tony Bennett’s family announced last February that
Please fill out the form below to receive our e-newsletter.
Tomorrow’s treatment today.
541 S. Orlando Ave. #100, Orlando, FL 32751
